This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
After years of developing the device, BrainsWay has invested $8.5 million to strengthen the Brain disorder treatment business. Now, the company is set to launch its device consisting of a helmet lined with coils that deliver magnetic stimulation to the brain.